EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Analysis of Clinical Impact of CD33 rs12459419 Single-Nucleotide Polymorphism in AML Treated with Intensive Chemotherapy Without Gemtuzumab Ozogamicin

Sophie Helfenstein, Inna Shaforostova, Katja Seipel, Marie-Noelle Kronig, Myriam Legros, Ulrike Bacher iD, Thomas Pabst iD

International Journal of Molecular Sciences · 30.04.2026 · 27 (9) · 4050

DOI: 10.3390/ijms27094050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 30.04.2026. Verfasst von Sophie Helfenstein und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland. Hauptthemen laut MEDLINE: Sialic Acid Binding Ig-like Lectin 3, Polymorphism, Single Nucleotide, Leukemia, Myeloid, Acute. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The CD33 rs12459419 (C>T; Ala14Val) single-nucleotide polymorphism (SNP) has been reported to modulate treatment response and survival in pediatric patients with acute myeloid leukemia (AML) receiving gemtuzumab ozogamicin (GO), an anti-CD33 antibody linked to the cytotoxic compound calicheamicin. However, it remains unclear whether this SNP also affects CD33 expression on leukemic blasts. Moreover, its prognostic significance in adult AML patients treated with standard chemotherapy without GO has not been investigated. In this study, we retrospectively genotyped 184 adult AML patients who received standard induction chemotherapy for the CD33 rs12459419 SNP genotype and collected CD33 expression data. The observed genotype distribution was 46% (n = 85) CC, 43% (n = 79) CT, and 11% (n = 20) TT. CD33 expression was detected in significantly higher proportions of leukemic blasts in patients with the CC genotype than those with the TT genotype (p = 0.0009). A similar trend was observed between the CT and TT genotypes (p = 0.06). No significant differences in clinical outcome were detected among the three genotype cohorts. Grouping CC and CT genotypes together based on their similar CD33 expression and comparing them to patients with the TT genotype also revealed no differences in overall survival (OS), event-free survival (EFS), or relapse-free survival (RFS). Using a proportion of 90% CD33-positive blasts to define high versus low expression groups also failed to identify a meaningful impact on OS, EFS, or RFS, either across genotypes or independent of genotype. In conclusion, our findings indicate that the CD33 rs12459419 SNP does not affect outcomes or survival in adult AML patients receiving standard chemotherapy in the absence of GO. Furthermore, no association was seen between CD33 expression and clinical outcomes between the three genotypes. To our knowledge, this is the first study to investigate the prognostic impact of the CD33 rs12459419 SNP per se on outcome and survival in adult AML patients treated with chemotherapy without GO. Validation in larger patient cohorts is required to conclusively rule out a prognostic role of the CD33 rs12459419 SNP in AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sialic Acid Binding Ig-like Lectin 3Polymorphism, Single NucleotideLeukemia, Myeloid, AcuteHumansGemtuzumabFemaleAdultMaleMiddle AgedAgedGenotypePrognosisRetrospective StudiesYoung AdultAminoglycosidesAdolescentAged, 80 and over

Stichwörter der Autor:innen

CD33acute myeloid leukemia (AML)rs12459419single nucleotide polymorphism (SNP)

Substanzen

Sialic Acid Binding Ig-like Lectin 3GemtuzumabCD33 protein, humanAminoglycosides

Autor:innen und Institutionen

  • Department of Medical Oncology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland.
  • Department for Biomedical Research, University of Bern, 3008 Bern, Switzerland.
  • Department of Hematology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland.

ORCID-Profile: Ulrike Bacher, Thomas Pabst

Zitieren

APA

Helfenstein, S., Shaforostova, I., Seipel, K., Kronig, M. N., Legros, M., Bacher, U., & Pabst, T. (2026). Analysis of Clinical Impact of CD33 rs12459419 Single-Nucleotide Polymorphism in AML Treated with Intensive Chemotherapy Without Gemtuzumab Ozogamicin. International Journal of Molecular Sciences, 27(9), 4050. https://doi.org/10.3390/ijms27094050

Vancouver

Helfenstein S, Shaforostova I, Seipel K, Kronig MN, Legros M, Bacher U, et al. Analysis of Clinical Impact of CD33 rs12459419 Single-Nucleotide Polymorphism in AML Treated with Intensive Chemotherapy Without Gemtuzumab Ozogamicin. International Journal of Molecular Sciences. 2026;27(9):4050. doi:10.3390/ijms27094050

BibTeX
@article{Helfenstein2026,
  author = {Helfenstein, Sophie and Shaforostova, Inna and Seipel, Katja and Kronig, Marie-Noelle and Legros, Myriam and Bacher, Ulrike and Pabst, Thomas},
  title = {Analysis of Clinical Impact of CD33 rs12459419 Single-Nucleotide Polymorphism in AML Treated with Intensive Chemotherapy Without Gemtuzumab Ozogamicin},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {9},
  pages = {4050},
  doi = {10.3390/ijms27094050}
}
Kostenlos starten →